| SC 13G/A | 2024-02-14 | TANG CAPITAL PARTNERS LP | Quince Therapeutics, Inc. | 3,220,000 | 7.5% | EDGAR |
| SC 13G | 2024-02-12 | Sofinnova Partners SAS | Quince Therapeutics, Inc. | 2,178,150 | 5.1% | EDGAR |
| SC 13G/A | 2024-02-07 | BML Investment Partners, L.P. | Quince Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2023-12-15 | Genextra S.p.A. | Quince Therapeutics, Inc. | 2,525,950 | 5.9% | EDGAR |
| SC 13G | 2023-07-17 | BML Investment Partners, L.P. | Quince Therapeutics, Inc. | 1,466,201 | 4.0% | EDGAR |
| SC 13G | 2023-03-31 | TANG CAPITAL PARTNERS LP | Quince Therapeutics, Inc. | 3,620,000 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-13 | EPQ LLC, CTYM PS | Quince Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-07-08 | Capital World Investors | Cortexyme, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | PFIZER INC | Cortexyme, Inc. | 600,000 | 2.0% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital Research Global Investors | Cortexyme, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital World Investors | Cortexyme, Inc. | 2,501,882 | 8.4% | EDGAR |
| SC 13G/A | 2021-12-10 | Capital International Investors | Cortexyme, Inc. | 1,462,465 | 4.9% | EDGAR |
| SC 13G/A | 2021-12-10 | Capital International Investors | Cortexyme, Inc. | 1,462,465 | 4.9% | EDGAR |
| SC 13G/A | 2021-10-08 | Capital International Investors | Cortexyme, Inc. | 2,976,489 | 10.0% | EDGAR |
| SC 13G/A | 2021-10-08 | Capital International Investors | Cortexyme, Inc. | 2,976,489 | 10.0% | EDGAR |
| SC 13G/A | 2021-04-27 | Lamond David | Cortexyme, Inc. | 2,048,938 | 6.9% | EDGAR |
| SC 13G/A | 2021-03-25 | PFIZER INC | Cortexyme, Inc. | 2,056,377 | 7.0% | EDGAR |
| SC 13G/A | 2021-03-10 | Capital World Investors | Cortexyme, Inc. | 3,170,731 | 10.7% | EDGAR |
| SC 13G/A | 2021-02-16 | PFIZER INC | Cortexyme, Inc. | 2,143,372 | 7.3% | EDGAR |
| SC 13G/A | 2021-02-16 | Capital Research Global Investors | Cortexyme, Inc. | 2,605,753 | 8.8% | EDGAR |